We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App





More Than 90% of COVID-19 Patients Produce Strong Antibody Response to SARS-CoV-2 That Lasts for Many Months

By HospiMedica International staff writers
Posted on 30 Oct 2020
Print article
Image: More Than 90% of COVID-19 Patients Produce Strong Antibody Response to SARS-CoV-2 That Lasts for Many Months (Photo courtesy of Mount Sinai)
Image: More Than 90% of COVID-19 Patients Produce Strong Antibody Response to SARS-CoV-2 That Lasts for Many Months (Photo courtesy of Mount Sinai)
The vast majority of individuals infected with mild-to-moderate COVID 19 mount a robust antibody response that is relatively stable for at least five months, according to new research.

The research conducted by the Icahn School of Medicine at Mount Sinai (ISMMS New York, NY, USA) also found that this antibody response correlates with the body’s ability to neutralize (kill) SARS-CoV-2, the virus that causes COVID-19. These study findings are based on a dataset of 30,082 individuals, who were screened within the Mount Sinai Health System between March and October, 2020. The antibody test used in this research - an enzyme-linked immunosorbent assay (ELISA) - is based on the virus’s telltale spike protein that contains the machinery that enables it to attach and gain entry into human cells. The ELISA assay developed, validated, and launched at Mount Sinai detects the presence or absence of antibodies to SARS-CoV-2 and, importantly, is capable of measuring the titer (level) of antibodies an individual has. The high sensitivity and specificity of the test means that a false negative or false positive is highly unlikely.

The Mount Sinai data reveals antibody binding titers to the spike protein correlate significantly with neutralization of SARS-CoV-2 and that the vast majority of individuals with antibody titers of 320 or higher show neutralizing activity in their serum that are stable over a period of at least three months with only modest declines at the five-month time point. Although this cannot provide conclusive evidence that these antibody responses protect from reinfection, the team believes it is very likely that the antibodies will decrease the odds of getting reinfected and may attenuate disease in the case of breakthrough infection.

“While some reports have come out saying antibodies to this virus go away quickly, we have found just the opposite - that more than 90% of people who were mildly or moderately ill produce an antibody response strong enough to neutralize the virus, and the response is maintained for many months,” said Florian Krammer, PhD, Professor of Vaccinology at the Icahn School of Medicine at Mount Sinai and a senior author of the paper.

Related Links:
Icahn School of Medicine at Mount Sinai

Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Blanket Warming Cabinet
EC250
New
Monitor Cart
Tryten S5

Print article

Channels

Surgical Techniques

view channel
Image: The new treatment combination for subdural hematoma reduces the risk of recurrence (Photo courtesy of Neurosurgery 85(6):801-807, December 2019)

Novel Combination of Surgery and Embolization for Subdural Hematoma Reduces Risk of Recurrence

Subdural hematomas, which occur when bleeding happens between the brain and its protective membrane due to trauma, are common in older adults. By 2030, chronic subdural hematomas are expected to become... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.